CompletedPhase 2NCT00215202
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Studying Adrenocortical carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Principal Investigator
- Vivek Samnotra, MDDartmouth-Hitchcock Medical Center
- Intervention
- Iressa (ZD1839)(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2007
Study locations (4)
- Kentuckiana Cancer Institute PLLC, Louisville, Kentucky, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Collaborators
AstraZeneca · M.D. Anderson Cancer Center · Dana-Farber Cancer Institute · Kentuckiana Cancer Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00215202 on ClinicalTrials.govOther trials for Adrenocortical carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06487481Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07189403A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerDaiichi Sankyo
- RECRUITINGPHASE2NCT06587802Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical CarcinomaSun Yat-sen University
- RECRUITINGNCT06279442Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian CohortLatin American Cooperative Oncology Group
- RECRUITINGPHASE2NCT06333314Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIUNICANCER
- RECRUITINGPHASE2NCT06066333Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT05563467Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Maria Sklodowska-Curie National Research Institute of Oncology
- RECRUITINGPHASE2NCT05913427Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia